Senhwa Biosciences, Inc. 6492.TWO Stock

Senhwa Biosciences, Inc., a drug development company, engages in the development of new drugs and special pharmaceutical ingredients. The company develops CX-5461, a phase I, open-label, dose escalation, safety, pharmacokinetic, and pharmacodynamics study of intravenously administered CX-5461 in patients with advanced hematologic malignancies; and CX-5461 CA, which is in phase I clinical trials in patients with solid tumors and BRCA2 and/or PALB2 mutation. It is also developing CX-4945 that is in phase I/II clinical trial in combination with gemcitabine for the treatment of patients with cholangiocarcinoma; CX-4945-07, which is in phase I, multi-center, open-label, treatment duration increment, expansion, safety, and pharmacodynamic study of CX-4945 administered orally twice daily to patients with advanced basal cell carcinoma; and CX-4945-MB, a pediatric brain tumor consortium that is in phase I/II and surgical study of CX-4945 in patients with recurrent SHH medulloblastoma. In addition, the company develops CX-1945-Moderate COVID-19, a phase II, randomized and controlled investigator-initiated trial evaluating safety, pharmacokinetics and clinical benefits of silmitasertib in outpatient adult subjects with moderate coronavirus disease 2019; and CX-1945-Severe COVID-19, a phase II, randomized, and investigator-initiated trial evaluate safety and explore clinical benefits of silmitasertib in patients with severe coronavirus disease 2019. Senhwa Biosciences, Inc. was incorporated in 2012 and is based in New Taipei City, Taiwan.